-The Hindu Not only is tuberculosis not going away, we are now seeing severe forms of multi-drug resistant tuberculosis (MDR-TB) India accounts for a quarter of the 8.6 million cases of TB that occur worldwide. India also accounts for a third of the ‘missing 3 million TB cases' that do not get diagnosed or notified. Not only is TB not going away, we are now seeing severe forms of multi-drug resistant TB...
More »SEARCH RESULT
Total Matching Records found : 49
Cheap medicine myth busted -GS Mudur
-The Telegraph New Delhi: The rules for price caps on 348 medicines imposed by the central government last year provide drug companies "escape routes" and promise little relief to consumers, a report released today has warned. The report from the Public Health Foundation of India (PHFI), an academic institution, has also cautioned that the Drug Price Control Order (DPCO) rules will encourage the growth of irrational combinations of drugs that remain outside...
More »80% of medicines not covered by price control order -Rema Nagarajan
-The Times of India About 38 million people in India (which is more than Canada's population) fall below the poverty line every year due to healthcare expenses, of which 70% is on purchase of drugs. Yet, the much-awaited drug price control order (DPCO) 2013, meant to control the price of medicines does not cover over 80% of the medicines in the market. Many drugs crucial for India's disease profile have been...
More »Drug price control covers too little, riddled with loopholes -GS Mudur
-The Telegraph New Delhi: The price caps imposed by the Indian government on 348 drugs earlier this year have created only an illusion of control, keeping many medicines for conditions ranging from asthma to diabetes and heart disease beyond price regulations, experts said today. The price control order issued by the department of pharmaceuticals in May has led to a 22 per cent reduction in the average cost of some 250 medicines,...
More »Questions about India’s drug industry-Narayan Lakshman
-The Hindu Unless a deeper, institutional change is ushered in to break the nexus between drug companies and the regulatory regime, Indians consuming drugs may be exposing themselves to serious risks Even before I walked into the Mayflower Hotel in the heart of Washington on a crisp autumn afternoon to meet Dinesh Thakur, whistle-blower and former director of India-based pharmaceutical giant Ranbaxy, I had a hunch that this conversation would spark some...
More »
